Papers - HIRASAWA Akira

季節による漢方製剤の切り替えが片頭痛発作の軽減に有効であった1例

HIRASAWA AKIRA

産婦人科漢方研究のあゆみ   25   115-118   2008

　More details

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

季節による漢方製剤の切り替えが片頭痛発作の軽減に有効であった1例.

牧田和也, 平沢 晃, 冨永英一郎, 堀口 文, 青木大輔, 吉村泰典

産婦人科漢方研究のあゆみ   25 ( 25 )   115-118 - 118   2008

　More details

Language：Japanese  

researchmap

当科更年期外来にて診断し得た骨粗鬆症/骨量減少症における低エストロゲン血症以外の危険因子の検討.

牧田和也, 冨永英一郎, 平沢 晃, 堀口 文, 青木大輔

Osteoporosis Japan   16 ( 2 )   308 - 308   2008

　More details

Language：Japanese  

researchmap

当科更年期外来受診者におけるアレンドロネート製剤のweekly投与への切り替えの現状.

牧田和也, 平沢 晃, 冨永英一郎, 堀口 文, 青木大輔

Osteoporosis Japan   16 ( 3 )   268-269 - 469   2008

　More details

Language：Japanese  

researchmap

Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes

Kouji Banno, Megumi Yanokura, Makiko Kawaguchi, Yoshiko Kuwabara, Jyunko Akiyoshi, Yusuke Kobayashi, Takashi Iwata, Akira Hirasawa, Takuma Fujii, Nobuyuki Susumu, Kastumi Tsukazaki, Daisuke Aoki

INTERNATIONAL JOURNAL OF ONCOLOGY   31 ( 4 )   713 - 720   2007.10

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

A relationship between inactivation of mitotic checkpoint genes and sensitivity of cancer cells to anticancer agents has been reported. We investigated the effect of epigenetic inactivation by aberrant hypermethylation of the mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger) on the sensitivity of cervical cancer cells to taxanes. Methylation-specific PCR (MSP) of cervical smears showed aberrant methylation of CHFR in 12.3% (2/14) of adenocarcinoma specimens. In contrast, aberrant DNA methylation was not detected in normal cervical cells or squamous cell carcinoma cells. Aberrant methylation of CHFR was also analyzed in 6 human cervical carcinoma-derived cell lines and was observed in SKG-IIIb and HeLa cells. These cell lines showed high sensitivity to taxanes, but became taxane-resistant upon treatment with 5-azacytidine. Furthermore, suppression of CHFR expression in siRNA-transfected SKG-IIIa cells caused increased sensitivity to taxanes. In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. To our knowledge, this study is the first to examine epigenetic inactivation by aberrant hypermethylation of CHFR in cervical cancer.

Web of Science

researchmap

Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes Reviewed

Kouji Banno, Megumi Yanokura, Makiko Kawaguchi, Yoshiko Kuwabara, Jyunko Akiyoshi, Yusuke Kobayashi, Takashi Iwata, Akira Hirasawa, Takuma Fujii, Nobuyuki Susumu, Kastumi Tsukazaki, Daisuke Aoki

INTERNATIONAL JOURNAL OF ONCOLOGY   31 ( 4 )   713 - 720   2007.10

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

A relationship between inactivation of mitotic checkpoint genes and sensitivity of cancer cells to anticancer agents has been reported. We investigated the effect of epigenetic inactivation by aberrant hypermethylation of the mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger) on the sensitivity of cervical cancer cells to taxanes. Methylation-specific PCR (MSP) of cervical smears showed aberrant methylation of CHFR in 12.3% (2/14) of adenocarcinoma specimens. In contrast, aberrant DNA methylation was not detected in normal cervical cells or squamous cell carcinoma cells. Aberrant methylation of CHFR was also analyzed in 6 human cervical carcinoma-derived cell lines and was observed in SKG-IIIb and HeLa cells. These cell lines showed high sensitivity to taxanes, but became taxane-resistant upon treatment with 5-azacytidine. Furthermore, suppression of CHFR expression in siRNA-transfected SKG-IIIa cells caused increased sensitivity to taxanes. In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. To our knowledge, this study is the first to examine epigenetic inactivation by aberrant hypermethylation of CHFR in cervical cancer.

Web of Science

researchmap

Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. International journal

Kouji Banno, Megumi Yanokura, Makiko Kawaguchi, Yoshiko Kuwabara, Jyunko Akiyoshi, Yusuke Kobayashi, Takashi Iwata, Akira Hirasawa, Takuma Fujii, Nobuyuki Susumu, Kastumi Tsukazaki, Daisuke Aoki

International journal of oncology   31 ( 4 )   713 - 20   2007.10

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

A relationship between inactivation of mitotic checkpoint genes and sensitivity of cancer cells to anticancer agents has been reported. We investigated the effect of epigenetic inactivation by aberrant hypermethylation of the mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger) on the sensitivity of cervical cancer cells to taxanes. Methylation-specific PCR (MSP) of cervical smears showed aberrant methylation of CHFR in 12.3% (2/14) of adenocarcinoma specimens. In contrast, aberrant DNA methylation was not detected in normal cervical cells or squamous cell carcinoma cells. Aberrant methylation of CHFR was also analyzed in 6 human cervical carcinoma-derived cell lines and was observed in SKG-IIIb and HeLa cells. These cell lines showed high sensitivity to taxanes, but became taxane-resistant upon treatment with 5-azacytidine. Furthermore, suppression of CHFR expression in siRNA-transfected SKG-IIIa cells caused increased sensitivity to taxanes. In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer. To our knowledge, this study is the first to examine epigenetic inactivation by aberrant hypermethylation of CHFR in cervical cancer.

Web of Science

PubMed

researchmap

進行子宮体癌の再発・予後因子としてのCOX-2とCD8陽性リンパ球についての検討

末盛 友浩, 進 伸幸, 鶴田 智彦, 市川 義一, 野村 弘行, 片岡 史夫, 平澤 晃, 冨永 英一郎, 阪埜 浩司, 鈴木 淳, 青木 大輔

日本癌治療学会誌   42 ( 2 )   508 - 508   2007.9

　More details

Language：Japanese   Publisher：(一社)日本癌治療学会  

researchmap

ヒトモノクローナル抗体HMMC-1の子宮体癌細胞に対する増殖抑制効果の検討

笈川 文子, 鈴木 淳, 冨永 英一郎, 末盛 友浩, 市川 義一, 野村 弘行, 片岡 史夫, 平澤 晃, 進 伸幸, 青木 大輔

日本臨床細胞学会雑誌   46 ( Suppl.2 )   448 - 448   2007.9

　More details

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

researchmap

卵巣明細胞腺癌におけるシアリダーゼ発現の多寡が腹膜播種形成に及ぼす影響の検討

AOKI DAISUKE

日本分子腫瘍マーカー研究会誌   22   39429 - 13   2007.4

　More details

Language：Japanese  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2007&ichushi_jid=J04910&link_issn=&doc_id=20070427330008&doc_link_id=10.11241%2Fjsmtmr.22.12&url=https%3A%2F%2Fdoi.org%2F10.11241%2Fjsmtmr.22.12&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif

卵巣癌の各組織型特異的バイオマーカーに基づく診断用マイクロアレイDNAチップ作成

鈴木 淳, 杉田 哲佳, 東口 敦史, 末盛 友浩, 市川 義一, 野村 弘行, 平澤 晃, 玉田 裕, 進 伸幸, 佐藤 孝明, 青木 大輔, 吉村 泰典

日本産科婦人科学会雑誌   59 ( 2 )   409 - 409   2007.2

　More details

Language：Japanese   Publisher：(公社)日本産科婦人科学会  

researchmap

Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer Reviewed

Megumi Yanokura, Kouji Banno, Makiko Kawaguchi, Nobumaru Hirao, Akira Hirasawa, Nobuyuki Susumu, Katsumi Tsukazaki, Daisuke Aoki

ONCOLOGY REPORTS   17 ( 1 )   41 - 48   2007.1

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

The relationship of aberrant DNA hypermethylation of cell cycle checkpoint genes with the sensitivity of cancer cells to anticancer drugs is a question of current interest. In this study, we investigated the relationship between aberrant hypermethylation of the CHFR (checkpoint with forkhead-associated and ring finger) mitotic checkpoint gene and sensitivity to taxanes in endometrial cancer. Methylation-specific PCR (MSP) indicated aberrant hypermethylation of CHFR in 12.0% (6/50) of endometrial cancer specimens, and suggested that aberrant hypermethylation is significantly more frequent in poorly differentiated adenocarcinoma (G3) (p < 0.05). Of six culture cell lines, SNG-II and HEC108 cells showed aberrant hypermethylation and reduced expression of CHFR. These cells had high sensitivity to taxanes but became resistant after demethylation. Cancer specimens with aberrant hypermethylation of CHFR also exhibited high sensitivity to taxanes. To our knowledge, this study is the first to examine aberrant hypermethylation of CHFR in endometrial cancer, and our results suggest that the methylation status of CHFR may be a new molecular index that will allow design of personalized treatment in endometrial cancer. This may be particularly important in poorly differentiated adenocarcinoma (G3), which is known to have a poor prognosis.

Web of Science

researchmap

Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer

Megumi Yanokura, Kouji Banno, Makiko Kawaguchi, Nobumaru Hirao, Akira Hirasawa, Nobuyuki Susumu, Katsumi Tsukazaki, Daisuke Aoki

ONCOLOGY REPORTS   17 ( 1 )   41 - 48   2007.1

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

The relationship of aberrant DNA hypermethylation of cell cycle checkpoint genes with the sensitivity of cancer cells to anticancer drugs is a question of current interest. In this study, we investigated the relationship between aberrant hypermethylation of the CHFR (checkpoint with forkhead-associated and ring finger) mitotic checkpoint gene and sensitivity to taxanes in endometrial cancer. Methylation-specific PCR (MSP) indicated aberrant hypermethylation of CHFR in 12.0% (6/50) of endometrial cancer specimens, and suggested that aberrant hypermethylation is significantly more frequent in poorly differentiated adenocarcinoma (G3) (p < 0.05). Of six culture cell lines, SNG-II and HEC108 cells showed aberrant hypermethylation and reduced expression of CHFR. These cells had high sensitivity to taxanes but became resistant after demethylation. Cancer specimens with aberrant hypermethylation of CHFR also exhibited high sensitivity to taxanes. To our knowledge, this study is the first to examine aberrant hypermethylation of CHFR in endometrial cancer, and our results suggest that the methylation status of CHFR may be a new molecular index that will allow design of personalized treatment in endometrial cancer. This may be particularly important in poorly differentiated adenocarcinoma (G3), which is known to have a poor prognosis.

Web of Science

researchmap

Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. International journal

Megumi Yanokura, Kouji Banno, Makiko Kawaguchi, Nobumaru Hirao, Akira Hirasawa, Nobuyuki Susumu, Katsumi Tsukazaki, Daisuke Aoki

Oncology reports   17 ( 1 )   41 - 8   2007.1

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

The relationship of aberrant DNA hypermethylation of cell cycle checkpoint genes with the sensitivity of cancer cells to anticancer drugs is a question of current interest. In this study, we investigated the relationship between aberrant hypermethylation of the CHFR (checkpoint with forkhead-associated and ring finger) mitotic checkpoint gene and sensitivity to taxanes in endometrial cancer. Methylation-specific PCR (MSP) indicated aberrant hypermethylation of CHFR in 12.0% (6/50) of endometrial cancer specimens, and suggested that aberrant hypermethylation is significantly more frequent in poorly differentiated adenocarcinoma (G3) (p<0.05). Of six culture cell lines, SNG-II and HEC108 cells showed aberrant hypermethylation and reduced expression of CHFR. These cells had high sensitivity to taxanes but became resistant after demethylation. Cancer specimens with aberrant hypermethylation of CHFR also exhibited high sensitivity to taxanes. To our knowledge, this study is the first to examine aberrant hypermethylation of CHFR in endometrial cancer, and our results suggest that the methylation status of CHFR may be a new molecular index that will allow design of personalized treatment in endometrial cancer. This may be particularly important in poorly differentiated adenocarcinoma (G3), which is known to have a poor prognosis.

Web of Science

PubMed

researchmap

家族内癌集積性を有する子宮体癌症例におけるMMR遺伝子の生殖細胞変異解析

HIRASAWA AKIRA

家族性腫瘍   7 ( 1 )   15-18 - 18   2007

　More details

Language：Japanese  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2007&ichushi_jid=J03931&link_issn=&doc_id=20080620410004&doc_link_id=%2Fcg3kazok%2F2007%2F000701%2F005%2F0015-0018%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcg3kazok%2F2007%2F000701%2F005%2F0015-0018%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

妊娠に伴い増悪した片頭痛に対して呉茱萸湯が著効した１例―妊娠期間中の片頭痛治療に関する考察も含めて―

HIRASAWA AKIRA

産婦人科漢方研究のあゆみ   24 ( 24 )   98-101 - 101   2007

　More details

Language：Japanese  

researchmap

当院更年期外来にて診断された閉経後骨粗鬆症/骨量減少症における血清脂質動態の検討

HIRASAWA AKIRA

Osteoporosis Japan   15 ( 2 )   158   2007

　More details

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

骨粗鬆症治療薬の服薬コンプライアンス向上に必要な要因の検討

HIRASAWA AKIRA

Osteoporosis Japan   15 ( 3 )   142-144 - 486   2007

　More details

Language：Japanese  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2007&ichushi_jid=J03021&link_issn=&doc_id=20070808110032&doc_link_id=%2Fai6ostoe%2F2007%2F001503%2F033%2F0484-0486%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fai6ostoe%2F2007%2F001503%2F033%2F0484-0486%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

明細胞腺癌

AOKI DAISUKE

産婦人科の実際   55 ( 13 )   2185-2193   2006.12

　More details

Language：Japanese   Publishing type：Research paper (scientific journal)  

researchmap

Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Reviewed International journal

Kouji Banno, Megumi Yanokura, Nobuyuki Susumu, Makiko Kawaguchi, Nobumaru Hirao, Akira Hirasawa, Katsumi Tsukazaki, Daisuke Aoki

Oncology reports   16 ( 6 )   1189 - 96   2006.12

　More details

Language：English   Publishing type：Research paper (scientific journal)   Publisher：PROFESSOR D A SPANDIDOS  

Epigenetic abnormalities including the aberrant DNA hypermethylation of the promoter CpG islands play a key role in the mechanism of gene inactivation in cell carcinogenesis. To identify the genes associated with aberrant DNA hypermethylation in endometrial carcinogenesis, we studied the hypermethylation of the promoter regions of five genes: hMLH1, APC, E-cadherin, RAR-beta and p16. The frequencies of aberrant hypermethylation were 40.4% (21/52) in hMLH1, 22% (11/50) in APC, 14% (7/50) in E-cadherin, and 2.3% (1/44) in RAR-beta in endometrial cancer specimens. No aberrant DNA methylation was found in p16. In atypical endometrial hyperplasia, the frequencies of aberrant methylation were 14.3% (2/14) in hMLH1 and 7.3% (1/14) in APC, whereas normal endometrial cells showed no aberrant hypermethylation of any of the five genes. The high frequencies of the aberrant DNA hypermethylation of hMLH1, APC and E-cadherin suggest that the methylation of the DNA mismatch repair and Wnt signal-related genes may be associated with endometrial carcinogenesis.

Web of Science

PubMed

researchmap